Huan Tang

发表

Gene expression screening identifies CDCA5 as a potential therapeutic target in acral melanoma.

C. Cui, L. Si, Z. Chi, 2018, Human Pathology.

Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy

C. Cui, B. Lian, L. Si, 2017, Clinical Cancer Research.

Increased AURKA Gene Copy Number Correlates with Poor Prognosis and Predicts the Efficacy of High-dose Interferon Therapy in Acral Melanoma

C. Cui, L. Si, Z. Chi, 2018, Journal of Cancer.

Methylation of O6-methylguanine DNA methyltransferase promoter is a predictive biomarker in Chinese melanoma patients treated with alkylating agents

L. Si, Z. Chi, X. Sheng, 2018, Translational Cancer Research.

First-Line Osimertinib in Patients With EGFR-Mutated Non-Small Cell Lung Cancer: Effectiveness, Resistance Mechanisms, and Prognosis of Different Subsequent Treatments

Yong He, Z. Ding, Li Li, 2022, Clinical Medicine Insights. Oncology.

TERT copy gain predicts the outcome of high-dose interferon α-2b therapy in acral melanoma

J. Dai, C. Cui, L. Si, 2018, OncoTargets and therapy.

RBCK1 promotes p53 degradation via ubiquitination in renal cell carcinoma

C. Cui, L. Si, Z. Chi, 2019, Cell Death & Disease.

Analysis of NRAS gain in 657 patients with melanoma and evaluation of its sensitivity to a MEK inhibitor.

K. Brown, X. Bai, C. Cui, 2018, European journal of cancer.

Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Xiaowei Xu, C. Cui, L. Si, 2015, Clinical Cancer Research.

Systemic Immune-Inflammation Index and Circulating T-Cell Immune Index Predict Outcomes in High-Risk Acral Melanoma Patients Treated with High-Dose Interferon

C. Cui, L. Si, Z. Chi, 2017, Translational oncology.

PI3K/AKT/mTOR pathway inhibitors inhibit the growth of melanoma cells with mTOR H2189Y mutations in vitro

C. Cui, L. Si, Z. Chi, 2018, Cancer biology & therapy.

Identification of coexistence of BRAF V600E mutation and EZH2 gain specifically in melanoma as a promising target for combination therapy

Siming Li, C. Cui, B. Lian, 2017, Journal of Translational Medicine.

Analysis of TSC1 mutation spectrum in mucosal melanoma

C. Cui, L. Si, Z. Chi, 2018, Journal of Cancer Research and Clinical Oncology.

MicroRNA-23a-3p Inhibits Mucosal Melanoma Growth and Progression through Targeting Adenylate Cyclase 1 and Attenuating cAMP and MAPK Pathways

Li Zhou, X. Bai, C. Cui, 2019, Theranostics.

Mutations in BRAF codons 594 and 596 predict good prognosis in melanoma

C. Cui, L. Si, Z. Chi, 2017, Oncology letters.

High G2 and S‐phase expressed 1 expression promotes acral melanoma progression and correlates with poor clinical prognosis

C. Cui, L. Si, Z. Chi, 2018, Cancer science.

Clinical significance of BRAFV600E mutation in circulating tumor DNA in Chinese patients with melanoma.

C. Cui, L. Si, Z. Chi, 2017, Oncology letters.

Establishment and characterization of melanoma patient-derived xenograft models for preclinical evaluation of novel therapeutics

C. Cui, L. Si, Z. Chi, 2018, Melanoma research.

miR-let-7b and miR-let-7c suppress tumourigenesis of human mucosal melanoma and enhance the sensitivity to chemotherapy

C. Cui, L. Si, Z. Chi, 2019, Journal of experimental & clinical cancer research : CR.

miR-let-7b and miR-let-7c suppress tumourigenesis of human mucosal melanoma and enhance the sensitivity to chemotherapy

C. Cui, L. Si, Z. Chi, 2019, Journal of Experimental & Clinical Cancer Research.

RBCK1 promotes p53 degradation via ubiquitination in renal cell carcinoma

C. Cui, L. Si, Z. Chi, 2019, Cell Death & Disease.